Meta-analysis of 4 phase III trials (17,748 participants) of adjuvant CDK4/6 inhibitors in HR+/HER2− early breast cancer: iDFS benefit was similar in pre-/peri-menopausal (HR 0.80) and postmenopausal (HR 0.79) patients; no significant subgroup difference for iDFS or OS.
Meta-analysisn = 17,748
Bender et al. The impact of menopausal status on the efficacy of adjuvant CDK4/6 inhibitors in hormone receptor-positive early breast cancer: a systematic review and meta-analysis of phase III clinical trials